Semaglutide cut BMI more than liraglutide in Omani adults with T2DM or obesity

Both obesity and type 2 diabetes mellitus (T2DM) are prevalent chronic conditions, with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) emerging as effective treatments. Despite their widespread use, real-world comparative evidence for these agents, particularly from the Middle East, remains limited. This study addresses the gap by comparing the real-world effectiveness, adverse events, and adherence of semaglutide and liraglutide in an Omani adult population, providing crucial regional insights into their clinical application.

This retrospective cohort study analyzed 257 Omani adults (liraglutide n = 135; semaglutide n = 122) treated with once-weekly semaglutide or once-daily liraglutide from Jan 2024 to Dec 2025. The primary outcome was change in body mass index (BMI) at 3 and 6 months, plus body weight and total body weight loss. Propensity-score overlap weighting and a general linear model addressed group differences. Kaplan-Meier estimation assessed persistence. Semaglutide 2.4 mg was unavailable.

Written by TitrateLab, separately from the study summarized above.